The chemistry — and why it matters

Kratom (Mitragyna speciosa) leaf contains over 40 identified alkaloids. The two most studied are mitragynine, which makes up the majority of the alkaloid fraction (typically 60–70%), and 7-hydroxymitragynine (7-OH), which is a minor alkaloid present at less than 0.1% of dry leaf weight — and rarely more than 2% of total alkaloid content.

That ratio matters because 7-OH is dramatically more potent at the mu-opioid receptor than mitragynine. Published research has estimated 7-OH at roughly 10–13 times more potent than morphine on a per-molecule basis at that receptor. Mitragynine, by contrast, is a partial agonist with much weaker direct binding and a meaningfully different effect profile.

In a natural leaf product, the small amount of 7-OH is balanced and buffered by the much larger mitragynine fraction and a long tail of other alkaloids (speciogynine, paynantheine, speciociliatine, mitraphylline, and others). Strip that buffer away — by chemically isolating 7-OH or by semi-synthetic conversion from mitragynine to 7-OH — and you get a fundamentally different product. It looks like kratom on a label. It does not act like kratom in the body.

How synthetic 7-OH products entered the market

Around 2023, products labeled as concentrated 7-hydroxymitragynine — small tablets, gummies, and shots — began appearing in vape shops, gas stations, and online kratom retailers. Branding often invoked kratom heritage ("7-Tabs," "7-OH Pure," "Mitra-7"), and consumers reasonably assumed they were buying a stronger version of the same plant they already knew.

They weren't. The pharmacology is much closer to a synthetic opioid than to a traditional kratom leaf preparation. Reports of dependence, withdrawal severity, and overdose-style adverse events climbed quickly — and because the products were marketed as kratom, they appeared in news coverage and clinical reports as kratom incidents, with predictable consequences for the natural-leaf market's regulatory standing.

The regulatory response in 2025–2026

Three things have happened roughly in parallel:

  1. FDA action. The FDA issued a public consumer alert in 2025 targeting concentrated 7-OH products specifically, warning of dependence and overdose risk. Several states and cities have moved on enforcement actions following the alert.
  2. KCPA-style 7-OH caps. Most modern Kratom Consumer Protection Act implementations now include an explicit cap on 7-OH content relative to total alkaloid content — most commonly at 1–2% — which functionally bans the synthetic concentrates while protecting legitimate natural-leaf products.
  3. AKA position update. The American Kratom Association has made distinguishing natural kratom from synthetic 7-OH a central advocacy priority, urging members and policymakers to treat them as separate categories with separate rules.

The unifying logic is simple: protecting consumers from synthetic 7-OH is also what protects the legal future of natural kratom. The two goals aren't in tension; they are the same goal.

How to spot a synthetic 7-OH product at the shelf

1. Check the marketed name and primary ingredient

If the product's name or front-label callout emphasizes "7-OH," "7-hydroxy," "7-Tab," "Mitra-7," or similar — and especially if it is sold as a high-strength single-dose tablet or gummy — assume it is a concentrated 7-OH product unless the COA proves otherwise. Natural kratom is rarely if ever sold this way.

2. Read the COA — really read it

Every legitimate kratom product should have a per-batch Certificate of Analysis. On the alkaloid panel, look at the ratio of mitragynine to 7-OH:

  • Natural leaf or full-spectrum extract: mitragynine is by far the dominant alkaloid; 7-OH is typically less than 2% of total alkaloid content.
  • Synthetic 7-OH product: 7-OH is the dominant alkaloid by mass, often with mitragynine very low or absent.

3. Look at form factor

Real kratom is sold as: leaf powder, capsules, full-spectrum liquid extract, gummies that disclose mg of mitragynine per piece, and beverages like our MitraNade with disclosed alkaloid content. Synthetic 7-OH is most often sold as small high-strength tablets, "shots," or single-piece gummies with very high stated potency per unit and no full-spectrum disclosure.

4. Check vendor accreditation

AKA GMP Qualified Vendors are bound by the AKA's standards, which prohibit synthetic alkaloid products under the kratom label. Cross-reference any kratom brand you're evaluating against the AKA's public Qualified Vendor list. If they sell concentrated 7-OH products, they are not on it.

The 4 Leaf Herbals position

We don't make, sell, or distribute products presented as concentrated 7-OH. 4 Leaf Herbals publishes selected product- and batch-specific laboratory reports on its Lab Results page. Match the product and lot or batch identifier and review the 7-OH result shown; a report does not establish the composition of every product or lot.

We also actively support state-level KCPA legislation that caps 7-OH content, because the long-term legality of natural kratom depends on the synthetic concentrate market being regulated out of the kratom shelf entirely. If you're shopping for kratom in 2026, the single most important thing you can do is read the alkaloid ratio on the COA before you buy. Anything else is a guess. For a focused side-by-side comparison of natural kratom vs concentrated 7-OH products, see our kratom vs 7-OH products guide.